Optimistic Buy Rating for Mediwound: Strong Financials and Strategic Growth Initiatives Highlight Promising Future
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Craig-Hallum Maintains MediWound(MDWD.US) With Buy Rating, Announces Target Price $39
Mediwound (MDWD) Receives a New Rating From Craig-Hallum
MediWound Analyst Ratings
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Positive Outlook for Mediwound: Buy Rating Driven by Strong NexoBrid Momentum and Robust Pipeline
Craig-Hallum Maintains MediWound(MDWD.US) With Buy Rating
Craig-Hallum Initiates MediWound(MDWD.US) With Buy Rating, Announces Target Price $39
MediWound Analyst Ratings
Craig-Hallum Initiates Coverage On MediWound With Buy Rating, Announces Price Target of $39
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Mediwound (MDWD)
Buy Rating for Mediwound Driven by EscharEx's Market Potential and Disruptive Role in Chronic Wound Care
Citi Initiates MediWound(MDWD.US) With Buy Rating, Announces Target Price $25
MediWound Analyst Ratings
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Mediwound (MDWD) Receives a Buy From TD Cowen
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30